香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示，概不對因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何 責任。 本公告不會直接或間接在或向美國（包括美國的領土及屬地、任何州及哥倫比亞特區）發佈、刊 發及派發。本公告並不構成或組成於美國或任何其他司法權區購買或認購證券的任何要約或招 攬的一部分。本公告所述證券並無亦將不會根據1933年美國證券法（經不時修訂）（「美國證券 法」）或美國任何州的證券法登記。證券不得於美國境內或向美國人士（定義見美國證券法S規例 （「S規例」））或代表美國人士或為其利益提呈發售、出售、質押或轉讓，惟獲豁免遵守美國證券 法登記規定或屬毋須遵守美國證券法登記規定的交易除外。發售股份可於美國境外根據S規例 以離岸交易方式向非美國人士提呈、出售或交付。 本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。潛 在投資者於決定是否投資於藉此提呈發售的H股前，應細閱上海寶濟藥業股份有限公司（「本公 司」）日期為2025年1 ...

Core Viewpoint - The Hong Kong IPO market is experiencing significant activity, highlighted by the strong performance of new listings such as Baoji Pharmaceutical-B, which saw its stock price surge over 115% in pre-listing trading [1][2]. Group 1: Baoji Pharmaceutical-B - Baoji Pharmaceutical-B's stock price reached 56 HKD in dark pool trading, a 112.28% increase from its offering price of 26.38 HKD [2][3]. - The company raised 2.6921 billion HKD in margin financing, indicating an oversubscription rate of 2690.8 times against its public offering amount of 1 million HKD [1]. - The IPO attracted significant cornerstone investors, including prominent institutions that collectively subscribed for 200.6 million HKD, accounting for 20.06% of the total fundraising [4]. Group 2: Company Overview - Established in 2019 and headquartered in Shanghai, Baoji Pharmaceutical is a biotechnology company focused on developing and providing recombinant biopharmaceuticals [4]. - The company has a pipeline of 12 in-development products, including three core products, with one recently approved for market and others in various stages of clinical trials [4]. Group 3: Financial Performance - Baoji Pharmaceutical has not yet achieved profitability, with projected revenues of 6.93 million HKD and 6.16 million HKD for 2023 and 2024, respectively, and net losses of 160 million HKD and 364 million HKD [5]. - In the first half of 2025, the company expects a revenue increase to 41.99 million HKD, a year-on-year growth of 2716.23%, although it will still incur a net loss of 183 million HKD [5]. Group 4: Market Trends - The Hong Kong IPO market has been robust, with 91 companies completing IPOs in the first 11 months of the year, raising a total of 259.889 billion HKD, a 228% increase year-on-year [10]. - The average oversubscription rate for Hong Kong IPOs in 2025 reached 1675 times, a significant increase compared to previous years, indicating heightened investor interest [10]. - The average first-day return for new listings in 2025 was 38%, a substantial increase of 347 percentage points from the previous year, with the first-day loss rate dropping to 23.08%, the lowest in five years [10].

本文源自：智通财经网 智通财经获悉，12月9日，宝济药业-B(02659)暗盘交易涨势如虹，市场情绪高涨。截至收盘，暗盘交易 显示报价56.5港元，较招股价26.38港元上涨114.18%，涨幅较开盘时进一步扩大，每手100股，不计手 续费，每手赚3012港元。宝济药业将于12月10日挂牌，中信证券、国泰海通为联席保荐人。 ...

12月9日，宝济药业-B(02659)暗盘交易涨势如虹，市场情绪高涨。截至收盘，利弗莫尔证券暗盘交易显 示报价56.5港元，较招股价26.38港元上涨114.18%，涨幅较开盘时进一步扩大，每手100股，不计手续 费，每手赚3012港元。宝济药业将于12月10日挂牌，中信证券、国泰海通为联席保荐人。 ...

智通财经APP获悉，12月9日，宝济药业-B(02659)暗盘交易涨势如虹，市场情绪高涨。截至收盘，利弗 莫尔证券暗盘交易显示报价56.5港元，较招股价26.38港元上涨114.18%，涨幅较开盘时进一步扩大，每 手100股，不计手续费，每手赚3012港元。宝济药业将于12月10日挂牌，中信证券、国泰海通为联席保 荐人。 ...

港股新股宝济药业-B(02659.HK)暗盘一度涨超100%。 本文源自：金融界AI电报 ...

Core Viewpoint - Baoyi Pharmaceutical-B (02659) has shown strong performance in the dark market, with a trading price of HKD 54, representing a 104.7% increase from the IPO price of HKD 26.38, indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Company Overview - Baoyi Pharmaceutical was established in 2019 and is headquartered in Shanghai, China, focusing on developing and providing recombinant biopharmaceuticals using advanced synthetic biotechnology [2] - The company has a pipeline of 12 self-developed products, including three core products (KJ017, KJ103, and SJ02), four other clinical candidates, and five preclinical assets [2] Group 2: Product and Market Potential - The core products and major assets of Baoyi Pharmaceutical are focused on four key therapeutic areas, including high-volume subcutaneous administration, antibody-mediated autoimmune diseases, assisted reproductive drugs, and innovative recombinant biopharmaceuticals [3] - The total clinical addressable market size for Baoyi Pharmaceutical's four strategic therapeutic areas in China is projected to reach approximately RMB 50 billion by 2033, with significant contributions from various segments [4] - The company has established a GMP-compliant production facility in Shanghai, covering approximately 63,000 square meters, equipped with specialized production lines for complex biopharmaceuticals [4] Group 3: Investment and Future Outlook - The IPO has attracted a strong lineup of cornerstone investors, with three well-known investment institutions participating, collectively subscribing to HKD 200.6 million, accounting for 20.06% of the total fundraising [1] - With sufficient funding and a clear strategy, Baoyi Pharmaceutical is expected to accelerate the commercialization of its core products and translate its technological advantages into tangible performance growth [4]

Core Viewpoint - Baoyi Pharmaceutical-B (02659) has shown strong performance in the dark market, with a trading price of HKD 54, representing a 104.7% increase from the IPO price of HKD 26.38, indicating strong investor interest and confidence in the company's future prospects [1] Group 1: IPO Details - Baoyi Pharmaceutical plans to issue 37.91 million H-shares, with 90% allocated for international offerings and 10% for public offerings in Hong Kong [1] - The IPO price is set at HKD 26.38 per share, with an entry fee of approximately HKD 2,664.60 per hand [1] - The company has attracted significant cornerstone investors, with three well-known institutions participating and collectively subscribing HKD 200.6 million, accounting for 20.06% of the total fundraising [1] Group 2: Company Overview - Established in 2019 and headquartered in Shanghai, Baoyi Pharmaceutical is a biotechnology company focused on developing and providing recombinant biopharmaceuticals using advanced synthetic biology technology [2] - The company has a pipeline of 12 self-developed products, including three core products (KJ017, KJ103, and SJ02) and four other clinical candidates [2] Group 3: Product Pipeline and Market Potential - Baoyi Pharmaceutical's core products target four key therapeutic areas, including high-volume subcutaneous administration and antibody-mediated autoimmune diseases, with KJ017 being a recombinant hyaluronidase and KJ103 being a novel IgG-degrading enzyme [2][3] - The clinical addressable market for Baoyi Pharmaceutical's four strategic therapeutic areas in China is projected to reach approximately RMB 50 billion by 2033, driven by significant market sizes in each area [3] - The company has established a GMP-compliant production facility in Shanghai, covering approximately 63,000 square meters, equipped with specialized production lines for complex biopharmaceuticals [3] Group 4: Growth Potential - With its innovative product pipeline, strong R&D capabilities, and advanced production capacity, Baoyi Pharmaceutical demonstrates significant growth potential [4] - The company's entry into the capital market, supported by ample funding and a clear strategy, is expected to accelerate the commercialization of its core products and translate technological advantages into tangible performance growth [4]

Shanghai Bao Pharmaceuticals Co., Ltd. 上海寶濟藥業股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2659） 董事名單與其角色和職能 上海寶濟藥業股份有限公司（「本公司」）董事（「董事」）會（「董事會」）成員載列如 下： 執行董事 劉彥君博士（ 聯合創始人、董事長兼執行董事 ） 王徵女士 譚靖偉先生 李翠女士 獨立非執行董事 蔡仲曦先生 曾凡一博士 鞠佃文博士 張森泉先生 1 非執行董事 董事會設立四個委員會。下表提供該等委員會的成員資料。 | | 董事委員會 | 審計委員會 | | 提名委員會 | 薪酬委員會 | 戰略委員會 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 董事 | | | | | | | | | 劉彥君博士 | | | | C | | C | | | 王徵女士 | | | | | M | | | | 譚靖偉先生 | | | | | | | | | 李翠女士 | | | | | | M | | | 林佳陵女士 | | | | | | | M | | 刁雋桓先生 | | | ...

上海寶濟藥業股份有限公司 董事會提名委員會工作細則 總則 第一條 為強化上海寶濟藥業股份有限公司（以下簡稱「公司」或「本公司」） 董事會決策功能，加強公司董事會對管理層的有效監督，完善公司治理結構，根 據《中華人民共和國公司法》（以下簡稱「《公司法》」）、《香港聯合交易所有限公司 證券上市規則》（以下簡稱「《香港上市規則》」）、《香港上市規則》附錄C1所載的 《企業管治守則》及H股發行後適用的《上海寶濟藥業股份有限公司章程》（以下簡 稱「《公司章程》」）及其他有關法律、行政法規和規範性文件，本公司設立董事會 提名委員會，並制定本工作細則。 第二條 提名委員會是董事會按照股東會決議設立的專門工作機構，對董事 會負責，其主要職責是對公司董事（包括獨立非執行董事）及高級管理人員的選 擇、選擇標準和程序進行研究並向董事會提出意見和建議。 第五條 提名委員會設召集人即委員會主席一名，由董事長或獨立非執行董 事擔任，由董事會任命及罷免，負責主持提名委員會工作。委員會主席不能或不 履行職責時，由二分之一以上委員共同推舉一名獨立非執行董事代行其職責。 1 第六條 提名委員會委員必須符合下列條件： 不符合前條規定的任職條件的人 ...